TY - JOUR
KW - Adult
KW - Alcoholism/drug therapy/therapy
KW - Combined Modality Therapy
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Naltrexone/adverse effects/analogs & derivatives/therapeutic use
KW - Neuroprotective Agents/therapeutic use
KW - Primary Health Care
KW - Psychotherapy
KW - Treatment Outcome
KW - Young Adult
KW - Alcohol dependence
KW - Clinical Trial
KW - Nalmefene
KW - primary care
AU - Philippe Castera
AU - Edmund Stewart
AU - Josef Grosskopf
AU - Carlos Brotons
AU - Maiken Brix Schou
AU - Doris Zhang
AU - Bjorn Steiniger Brach
AU - Didier Meulien
AU - on behalf of the PICASO Study Investigators
A1 - 
AD - Professeur Associe de Medecine Generale De l'Universite De Bordeaux, Cabinet Medical, Bordeaux, France, philippe.castera@u-bordeaux.fr.; NHS Lanarkshire Integrated Addiction Service, Coathill, Lanarkshire, United Kingdom.; Gemeinschaftspraxis, Innere und Allgemeinmedizin, Wallerfing, Germany.; Sardenya Primary Health Care Center, Biomedical Research Institute Sant PauPau (IIB-Sant Pau), Barcelona, Spain.; H. Lundbeck A/S, Valby, Denmark.; H. Lundbeck A/S, Valby, Denmark.; UCB Biopharma S.P.R.L, Brussels, Belgium.; H. Lundbeck A/S, Valby, Denmark.
BT - European addiction research
C5 - Opioids & Substance Use
CP - 6
CY - Switzerland
DO - 10.1159/000494692
IS - 6
JF - European addiction research
LA - eng
M1 - Journal Article
PB - S. Karger AG, Basel
PP - Switzerland
PY - 2018
SN - 1421-9891; 1022-6877
SP - 293
EP - 303
EP - 
T1 - Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care
T2 - European addiction research
TI - Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care
U1 - Opioids & Substance Use
U2 - 30485854
U3 - 10.1159/000494692
VL - 24
VO - 1421-9891; 1022-6877
Y1 - 2018
ER -